← All trials
NCT05774756
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 26, 2023
- Primary completion
- Apr 16, 2025
- Completion date
- Apr 16, 2025
- First posted
- Mar 20, 2023
- Last posted
- Dec 11, 2023
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rhythm Pharmaceuticals, Inc.Lead sponsor
- Rhythm Pharmaceuticals, Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.